Introduction Biohaven Pharmaceuticals is a company that focuses on discovering and developing drugs that target the glutamatergic system. These are substances that are currently in the clinical trial stage. The company was established in July 2013 and is based in New Haven, Connecticut. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Fusion protein | 1 |
CIK therapy | 1 |
Mechanism EAAT2 modulators [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MSTN inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AKT gene inhibitors [+2] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Start Date06 Jul 2022 |
Sponsor / Collaborator |
Start Date21 Oct 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
VT-1021 ( THBS1 ) | Glioblastoma Multiforme More | Phase 3 Clinical |
Paxalisib ( Akt x PI3K family x mTOR ) | Glioblastoma Multiforme More | Phase 3 Clinical |
Verdiperstat ( MPO ) | Amyotrophic Lateral Sclerosis More | Phase 3 Clinical |
Talditercept alfa ( MSTN ) | Spinal Muscular Atrophy More | Phase 3 |
Trigriluzole ( EAAT2 x NMDA receptor x Nav1.5 x VGSCs ) | Spinocerebellar Ataxia 10 More | Phase 3 |